Home/Pipeline/PTP1B Inhibitor

PTP1B Inhibitor

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

DepYmed

About DepYmed

DepYmed is a clinical-stage biotech leveraging a proprietary platform to develop selective inhibitors of protein tyrosine phosphatase 1B (PTP1B) and copper chelators. The company is advancing two orally bioavailable small molecules into clinical trials, with its lead asset, DPM-1003 for Rett Syndrome, having recently received FDA clearance to initiate a Phase 1 trial. With a focus on rare diseases and oncology, DepYmed is backed by venture capital and led by a team with deep expertise in drug development and phosphatase biology.

View full company profile

Therapeutic Areas

Rett Syndrome Oncology Wilson Disease Metabolic Diseases Neurodegenerative Diseases

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active